Stratos reached its milestone by demonstrating nanopore sequencing with its proprietary expandable nucleotides, called X-NTPs.
NEW YORK (GenomeWeb) – When Roche announced last month that it planned to acquire nanopore sequencing startup Genia for up to $350 million, unbeknownst to the public
NEW YORK (GenomeWeb) — Roche said today that it has made a strategic investment in nanopore sequencing startup Stratos Genomics and is collaborating to further develop the firm's sequencing chemistry.
After developing the chemistry for its sequencing-by-expansion nanopore technology for several years, Stratos Genomics is ready to grow its development and commercialization efforts.
NEW YORK (GenomeWeb News) – Stratos Genomics today announced it has closed on $2 million in financing to support the further development of, and "strategic discussions" related to the Seattle-based firm's DNA sequencing technology.
Stratos converts DNA into a longer polymer called an "Xpandomer," which encodes the base sequence through reporter molecules that have a high signal-to-noise ratio.
The funding follows $4 million raised last year and will be used to further develop the firm's ultra-low-cost nucleic acid sequencing technology.
The firm will use the funds to support further development of its "sequencing by expansion" technology.
Seattle-based Stratos Genomics, a 2007 spin-off from the Stratos Group, is working on a new method called sequencing by expansion.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.